GeneDx Updates Corporate Address & Contact Info in Routine 8-K

Ticker: WGSWW · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1818331

Genedx Holdings Corp. 8-K Filing Summary
FieldDetail
CompanyGenedx Holdings Corp. (WGSWW)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001, $379.50
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: administrative, corporate-governance

TL;DR

**GeneDx filed a routine 8-K updating its address and phone number; no big news here.**

AI Summary

GeneDx Holdings Corp. filed an 8-K on January 8, 2024, to update its corporate information, specifically its principal executive offices to 333 Ludlow Street, North Tower, 6th Floor, Stamford, Connecticut 06902, and its telephone number to (800) 298-6470. This filing also confirms its Class A common stock (WGS) and warrants are registered on The Nasdaq Stock Market LLC. For investors, this is a routine administrative update, indicating no material operational or financial changes, so it should not significantly impact their investment decisions.

Why It Matters

This filing is a standard administrative update, providing current contact and address details for GeneDx Holdings Corp. It doesn't signal any operational shifts or financial performance changes, so its impact on stock valuation is minimal.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative, updating contact information, and does not present any new financial or operational risks.

Analyst Insight

A smart investor would recognize this as a non-material administrative update and would not make any immediate trading decisions based solely on this filing. They would continue to monitor for filings related to financial performance, strategic changes, or operational developments.

Key Numbers

  • $0.0001 — par value per share (par value of Class A common stock)

Key Players & Entities

  • GeneDx Holdings Corp. (company) — the registrant filing the 8-K
  • 333 Ludlow Street, North Tower, 6th Floor, Stamford, Connecticut 06902 (address) — new principal executive offices
  • (800) 298-6470 (phone_number) — new registrant's telephone number
  • WGS (ticker) — trading symbol for Class A common stock
  • The Nasdaq Stock Market LLC (company) — exchange where securities are registered

FAQ

What is the new principal executive office address for GeneDx Holdings Corp. as reported in this 8-K?

The new principal executive office address for GeneDx Holdings Corp. is 333 Ludlow Street, North Tower, 6th Floor, Stamford, Connecticut 06902, as stated in the filing.

What is the updated telephone number for GeneDx Holdings Corp.?

The updated telephone number for GeneDx Holdings Corp. is (800) 298-6470, according to the 8-K filing.

What is the trading symbol for GeneDx Holdings Corp.'s Class A common stock?

The trading symbol for GeneDx Holdings Corp.'s Class A common stock is WGS, as listed under 'Securities registered pursuant to Section 12(b) of the Act'.

On which exchange are GeneDx Holdings Corp.'s securities registered?

GeneDx Holdings Corp.'s securities are registered on The Nasdaq Stock Market LLC, as indicated in the filing.

What was the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing was January 8, 2024, as stated in the 'Date of Report' section.

Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-01-08 08:58:39

Key Financial Figures

  • $0.0001 — stered Class A common stock, par value $0.0001 per share WGS The Nasdaq Stock Market L
  • $379.50 — mon stock, each at an exercise price of $379.50 per share WGSWW The Nasdaq Stock Market

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. The information set forth in Item 7.01 below is incorporated by reference into this Item 2.02.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2024, GeneDx Holdings Corp. (the " Company ") issued a press release (the " Press Release ") announcing the Company's expectations regarding its preliminary, unaudited revenue for the fourth quarter and the year ended 2023, exome and genome test result volumes for the fourth quarter and cash, cash equivalents, marketable securities and restricted cash as of December 31, 2023. A copy of the Press Release is included with this Form 8-K for convenience and attached hereto as Exhibit 99.1. Also on January 8, 2024, the Company is furnishing as Exhibit 99.2 hereto a copy of the investor presentation to be used at the 42nd Annual J.P. Morgan Healthcare Conference event. The information furnished under Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No Description 99.1 Press Release, dated January 8, 2024, regarding Preliminary 2023 Financial Results 99.2 Investor Presentation, dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GeneDx Holdings Corp. Date: January 8, 2024 By: /s/ Katherine Stueland Name: Katherine Stueland Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.